Table 1.
Summary of association of biomarkers with response to NAC based on the published studies.
| Ref | Biomarker | Patients (n) | Definition of Response | Results | ||
|---|---|---|---|---|---|---|
| Marker Pos/Responder (%) | Marker Pos/Nonresponder (%) | p-Value | ||||
| [52] | ATM, RB, FANCC | Discovery: 34 Validation: 24 |
≤pT1N0M0 | 13/15 (87%) 7/11 (64%) |
0/19 (0%) 2/13 (15%) |
<0.001 0.033 |
| [53] | ERCC2 | 50 | pT0/Tis | 9/25 (36%) | 0/25 (0%) | <0.05 |
| [54] | 48 | pT0/pTis/pTa | 8/20 (40%) | 2/28 (7%) | 0.01 | |
| [55] | 71 | pT0 | 6/38 (16%) | 2/33 (6%) | 0.27 | |
| [56] 1 | BRCA1 | 57 | ≤pT1N0M0 | 24/28 (85%) | 15/29 (52%) | 0.01 |
| [57] 2 | ERCC1 | 89 | ≤pT1N0M0 | 34/61 (56%) | 15/28 (54%) | 0.62 |
| [33] | P53 | 39 | pT0 | 7/14 (50%) | 12/25 (48%) | NS |
| [58] 3 | Emmprin, Survivin | 124 Emmprin Survivin Combination |
Not defined |
20/75 (27%) 24/74 (32%) 6/42 (14%) |
30/49 (61%) 28/50 (56%) 16/24 (67%) |
<0.05 <0.05 <0.05 |
| [55] | ERBB2 | 71 | pT0 | 9/38 (24%) | 0/33 (0%) | 0.003 |
| [59] | CTR1 | 44 | ≤pT1N0M0 pT0 |
13/20 (65%) 4/7 (57%) |
6/24 (25%) 15/37 (41%) |
0.0076 |
1 Low/intermediate levels of BRCA1 were associated with pathologic response to NAC. 2 ERCC1 negative patients had a prolonged RFS (10.6 mo vs. 8.4 mo, p = 0.03). 3 Emmprin and survivin-negative tumors were associated with improved response. Of note, combination category compares patients who were either positive or negative for both emmprin and survivin. NS: non-significant.